macuclear-old-couple-video-placeholder

Featured On

reuters logo

 

Stopping Dry Age-Related Macular Degeneration

People Would Rather Have a Heart Attack Than Go Blind!

MacuCLEAR, Inc. is driving innovation with the development of an eye drop treatment for the dry form of AMD, which affects around 15 million Americans and 30 million people globally. That’s 1 in 3 people over age 50. [ Learn More ]

home-image-mature-couple-beach

Learn More

learn more about MacuCLEAR and who we are

MacuCLEAR, Inc.: Who We Are

MacuCLEAR, Inc., a Texas Corporation, was formed in 2006 when it secured a worldwide license for a platform treatment for dry Age Related Macular Degeneration (dryAMD). More

about-our-dry-macular-degeneration-treatment

Our Treatment for Dry AMD

Currently, MacuCLEAR, Inc. is in development of an eye drop treatment for the dry form of AMD, which affects around 15 million Americans and 30 million people globally. More

macuclear-investment-opportunity-revolutionary-medicine

Your Investment Opportunity

MacuCLEAR, Inc.’s first phase 3 trial has been funded and its current preferred share offering has been closed. Additional funding for strategic partnering will be pursued for its second efficacy trial at the appropriate time. More